Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantation

2 Jul 2025

Abstract excerpt

This study examines the influence of single nucleotide polymorphisms in drug metabolizing enzymes CYP3A4, CYP3A5, and UGT1A4, and the transporter ABCB1 on tacrolimus dose requirements and blood trough level variability in the period immediately after liver transplantation. We analyzed genotypes for these genes in 61 adult liver transplant recipients who received tacrolimus and their respective donors. Significant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Pharmacological Effects and Toxicity Studies
Share to Renal Transplantation Outcomes and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40604035
DOI: 10.1038/s41598-025-09296-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantationPMID 40604035Read ↗

CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.Semantic proximity Read ↗

The CYP3A5 genotypes of both liver transplant recipients and donors influence the time‐dependent recovery of tacrolimus clearance during the early stage following transplantationSemantic proximity Read ↗

The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant CenterSemantic proximity Read ↗

Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.Semantic proximity Read ↗

The Impact of ABCB1 SNPs on Tacrolimus Pharmacokinetics in Liver or Kidney Transplant Recipients: A Meta-analysis.Semantic proximity Read ↗

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.Semantic proximity Read ↗

Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.Semantic proximity Read ↗

Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.Semantic proximity Read ↗

Analysis of ABCB1 Gene Polymorphisms and Their Impact on Tacrolimus Blood Levels in Kidney Transplant Recipients.Semantic proximity Read ↗

Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis.Semantic proximity Read ↗

Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.Semantic proximity Read ↗

CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.